Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8 + T-Cell Proliferation in Patients With Multiple Sclerosis.
Gianmarco AbbadessaMaria Teresa LeporeSara BruzzanitiErica PiemonteGiuseppina MieleElisabetta SignorielloFrancesco PernaChiara De FalcoGiacomo LusGiuseppe MatareseSimona BonavitaMario GalganiPublished in: Neurology(R) neuroimmunology & neuroinflammation (2024)
and NK cells, whose reduced cross-activity against myelin antigens might also contribute to its therapeutic efficacy during MS.